Explore the vast range of titles available.

Seaweed has recently become a rich source of valuable materials. Research showed that -carrageenan was insoluble in organic solvents and very soluble in water and inorganic solvents. The effects of alkali-metal cations on the gel-forming ability of the polysaccharide have been studied. The film- forming ability of -carrageenan was studied. The dissolution time of the film was found.

Carrageenans are valuable marine polysaccharides derived from specific species of red seaweed (Rhodophyta) widely used as thickening and stabilizing agents across various industries. Kappaphycus alvarezii, predominantly cultivated in tropical countries, is the primary source of kappa-carrageenan. Traditional industrial extraction methods involve alkaline treatment for up to three hours followed by heating, which is inefficient and generates substantial waste. Thus, developing improved extraction techniques would be helpful for enhancing efficiency and reducing environmental impacts, solvent costs, energy consumption, and the required processing time. In this study, we explored innovative extraction methods, such as ultrasound-assisted extraction (UAE) and supercritical water extraction (SFE), together with other extraction methods to produce kappa-carrageenan from a new strain of K. alvarezii from the Philippines. FTIR-ATR spectroscopy was employed to characterize the structure of the different carrageenan fractions. We also examined the physicochemical properties of isolated phycocolloids, including viscosity, and the content of fatty acids, proteins, and carbohydrates. For refined carrageenan (RC), both the traditional extraction method and the UAE method used 1 M NaOH. Additionally, UAE (8% KOH) was employed to produce semi-refined carrageenan (SRC). UAE (8% KOH) produced a high yield of carrageenan, in half the extraction time (extraction yield: 76.70 ± 1.44), and improved carrageenan viscosity (658.7 cP), making this technique highly promising for industrial scaling up. On the other hand, SFE also yielded a significant amount of carrageenan, but the resulting product had the lowest viscosity and an acidic pH, posing safety concerns as classified by the EFSA’s re-evaluation of carrageenan as a food additive.

Background The common cold is the most widespread viral infection in humans. Iota-carrageenan has previously shown antiviral effectiveness against cold viruses in clinical trials. This study investigated the efficacy of a carrageenan-containing nasal spray on the duration of the common cold and nasal fluid viral load in adult patients. Methods In a randomized, double-blind, placebo-controlled trial, 211 patients suffering from early symptoms of the common cold were treated for seven days. Application was performed three times daily with either a carrageenan-supplemented nasal spray or saline solution as placebo with an overall observation period of 21 days. The primary endpoint was the duration of disease defined as the time until the last day with symptoms followed by all other days in the study period without symptoms. During the study, but prior unblinding, the definition of disease duration was adapted from the original protocol that defines disease duration as the time period of symptoms followed by 48 hours without symptoms. Results In patients showing a laboratory-confirmed cold virus infection and adherence to the protocol, alleviation of symptoms was 2.1 days faster in the carrageenan group in comparison to placebo (p = 0.037). The primary endpoint that had been prespecified but was changed before unblinding was not met. Viral titers in nasal fluids showed a significantly greater decrease in carrageenan patients in the intention-to-treat population (p = 0.024) and in the per protocol population (p = 0.018) between days 1 and 3/4. Conclusions In adults with common cold virus infections, direct local administration of carrageenan with nasal sprays reduced the duration of cold symptoms. A significant reduction of viral load in the nasal wash fluids of patients confirmed similar findings from earlier trials in children and adults. Trial registration Current Controlled Trials ISRCTN80148028

Carrageenan is an anionic sulfated polysaccharide that accounts for a high content of red seaweed Eucheuma gelatinae. This paper focused on the extraction, optimization, and evaluation of antioxidant activity, rheology characteristics, and physic-chemistry characterization of β-carrageenan from Eucheuma gelatinae. The extraction and the optimization of β-carrageenan were by the maceration-stirred method and the experimental model of Box-Behken. Antioxidant activity was evaluated to be the total antioxidant activity and reducing power activity. The rheology characteristics of carrageenan were measured to be gel strength and viscosity. Physic-chemistry characterization was determined, including the molecular weight, sugar composition, function groups, and crystal structure, through GCP, GC-FID, FTIR, and XRD. The results showed that carrageenan possessed antioxidant activity, had intrinsic viscosity and gel strength, corresponding to 263.02 cps and 487.5 g/cm2, respectively. Antioxidant carrageenan is composed of rhamnose, mannose, glucose, fucose, and xylose, with two molecular weight fractions of 2.635 × 106 and 2.58 × 106 g/mol, respectively. Antioxidant carrageenan did not exist in the crystal. The optimization condition of antioxidant carrageenan extraction was done at 82.35 °C for 115.35 min with a solvent-to-algae ratio of 36.42 (v/w). At the optimization condition, the extraction efficiency of carrageenan was predicted to be 87.56 ± 5.61 (%), the total antioxidant activity and reducing power activity were predicted to 71.95 ± 5.32 (mg ascorbic acid equivalent/g DW) and 89.84 ± 5.84 (mg FeSO4 equivalent/g DW), respectively. Purity carrageenan content got the highest value at 42.68 ± 2.37 (%, DW). Antioxidant carrageenan from Eucheuma gelatinae is of potential use in food and pharmaceuticals.

Iota-carrageenan (I-C) is active against respiratory viruses in vitro and was effective as nasal spray in three previous clinical trials. The current trial served to further investigate I-C in patients with early common cold symptoms. Methods This randomized, placebo-controlled, double-blind phase IV trial was conducted in 200 adult patients with self-diagnosed colds of <48 h’ duration that were confirmed by baseline cold symptom scores. Patients were to self-administer 0.12 % I-C or placebo spray (NaCl 0.5 %) four times daily for four to ten days and record symptom information for ten days. Common respiratory viruses were quantified by RT-PCR during pretreatment and on Day 3 or 4. The primary endpoint was the mean total symptom score (TSS) of eight cold symptoms on Days 2–4 (TSS 2–4 ). Results Patients in both treatment groups had similar baseline TSSs (mean TSS: 6.75 for I-C and 6.79 for placebo). Viruses were detected in baseline samples from 53 of 98 I-C patients (54.1 %) and 54 of 97 placebo patients (55.7 %). Mean ± SE for TSS 2–4 was 5.78 ± 0.25 for I-C patients and 6.39 ± 0.25 for placebo ( p  = 0.0895). Exploratory analyses after unblinding (TSS 2–4 excluding a patient with aberrantly high symptom scores [TSS 2–4, ex 1pt ]; mean of TSS over Days 1–4 [TSS 1–4 ]; change in TSS 1–4 relative to baseline [TSS 1–4, rel ]) demonstrated treatment differences in favor of I-C ( p  = 0.0364, p  = 0.0495 and p  = 0.0421, respectively). For patients with quantifiable rhinovirus/enterovirus at baseline, there was a trend towards greater reduction of virus load at Day 3 or 4 ( p  = 0.0958; I-C: 90.2 % reduction in viral load; placebo: 72.0 %). Treatments were well tolerated with no differences in adverse event rates. Conclusions The primary endpoint did not demonstrate a statistically significant difference between I-C and placebo but showed a trend towards I-C benefit. Exploratory analyses indicated significant reduction of cold symptoms in the I-C group relative to placebo during the first four days when symptoms were most severe, and also substantiated I-C’s activity against rhinovirus/enterovirus. Trial registration NCT01944631 (clinicaltrials.gov)

Carrageenan, a natural polysaccharide derived from red algae, has garnered significant attention for its versatile applications in biomedical, pharmaceutical, and material sciences because of its inherent biological and gelling nature. Moreover, its intrinsic properties, including gel-forming ability, biocompatibility, and tunable viscosity, make it a valuable material for drug delivery, tissue engineering, and food technology. However, these properties can be further enhanced or tailored through chemical and structural modifications per the requirements of biomedicine. This review explores various modifications of carrageenan, such as functional and ionic modifications, that alter its physiological and biomedical properties. Common changes in hydrophobicity were found through the addition of extra carbon chains and functional groups; moreover, ionic changes also affected hydrophobicity and cancer cell selectivity in the case of barium ions, which were analysed through the encapsulation of a water-insoluble drug. The conductivity was also enhanced by ionic changes as well as the addition of aromatic groups to carrageenan, which could be utilized for ionic moments in tissue engineering and ion-linked targeted drug delivery. Overall, all of these modifications were crucial for resolving the limitations of the parent polymer (toxicity, conductivity and excessive hydrophilicity), expanding its range of possible uses and expanding its use in targeted drug delivery, cancer therapy, wound healing, and smart material development. This review delves into the underlying mechanisms of these modifications and highlights their impact on the biomedical and material science applications of carrageenan, providing a pathway for future innovations in this field.

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease driven by immune dysregulation and epidermal barrier dysfunction. Current therapeutic options are often limited by safety concerns or suboptimal tolerability. In this study, we isolated and structurally characterized GRB-H—a λ-carrageenan-enriched sulfated hybrid galactan from the marine red alga Gigartina radula—as a complex polysaccharide containing κ-, ι-, μ-, ν-, and λ-carrageenan structural units, and systematically evaluated its anti-AD potential using both in vitro and in vivo models. In vitro, GRB-H significantly suppressed lipopolysaccharide (LPS)-induced nitric oxide (NO), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) in RAW 264.7 macrophages, and reduced 2,4-dinitrochlorobenzene (DNCB)-evoked TNF-α and IL-1β expression in HaCaT keratinocytes. In a DNCB-induced murine model of AD, topical application of GRB-H markedly ameliorated skin inflammation, epidermal hyperplasia, and dermal immune cell infiltration. GRB-H treatment lowered total serum immunoglobulin E (IgE) levels, restored the imbalanced Th1/Th2 cell ratio in the spleen, and downregulated the mRNA expression of key inflammatory cytokines—including TNF-α, IL-4, IL-5, IL-31, and interferon-γ (IFN-γ)—in lesional skin. Collectively, these findings demonstrate that GRB-H alleviates AD symptoms through coordinated local anti-inflammatory and systemic immunomodulatory actions, highlighting its promise as a marine-derived candidate for the topical management of AD.

Carrageenan oligosaccharides (COSs) possess versatile activities and have drawn increasing attention in recent years. Due to their unique structures, COSs have been considered to be potential antibacterial agents and immune stimulators. Herein, we aimed to efficiently prepare the COSs by using a novel carrageenase CgkA from Zobellia uliginosa with high activity and further investigate the effects of dietary supplementation with COSs on the growth performance, serum biochemical parameters and non-specific immunity in Carassius auratus gibelio. The results indicated that the CgkA could effectively degrade the carrageenan into oligosaccharides with DPs of 2–6 and the oligosaccharides exhibited promoting effects on growth performance, serum biochemical index and non-specific immune parameters. After a 6-month feeding trial, the SR (Survival Ratio) was significantly higher in fish fed 0.1% (Diet 1), 0.2% (Diet 2), 0.5% (Diet 3) and 1% (Diet 4) COSs diets than that in the control group (p < 0.05). In addition, the supplementation of COSs decreased the malondialdehyde (MDA) content in the serum and increased the activity of lysozyme (LZM), superoxide dismutase (SOD) and catalase (CAT). In conclusion, COSs as a dietary supplement enhance the growth performance and non-specific immunity of crucian carp and their resistance to diseases.

The COVID-19 pandemic continues to spread around the world and remains a major public health threat. Vaccine inefficiency, vaccination breakthroughs and lack of supply, especially in developing countries, as well as the fact that a non-negligible part of the population either refuse vaccination or cannot be vaccinated due to age, pre-existing illness or non-response to existing vaccines intensify this issue. This might also contribute to the emergence of new variants, being more efficiently transmitted, more virulent and more capable of escaping naturally acquired and vaccine-induced immunity. Hence, the need of effective and viable prevention options to reduce viral transmission is of outmost importance. In this study, we investigated the antiviral effect of iota-, lambda- and kappa-carrageenan, sulfated polysaccharides extracted from red seaweed, on SARS-CoV-2 Wuhan type and the spreading variants of concern (VOCs) Alpha, Beta, Gamma and Delta. Carrageenans as part of broadly used nasal and mouth sprays as well as lozenges have the potential of first line defense to inhibit the infection and transmission of SARS-CoV-2. Here, we demonstrate by using a SARS-CoV-2 spike pseudotyped lentivirus particles (SSPL) system and patient-isolated SARS-CoV-2 VOCs to infect transgenic A549ACE2/TMPRSS2 and Calu-3 human lung cells that all three carrageenan types exert antiviral activity. Iota-carrageenan exhibits antiviral activity with comparable IC50 values against the SARS-CoV-2 Wuhan type and the VOCs. Altogether, these results indicate that iota-carrageenan might be effective for prophylaxis and treatment of SARS-CoV-2 infections independent of the present and potentially future variants.

Carrageenan-containing nasal sprays, available over-the-counter (OTC), are often marketed as having anti-viral effects. Carrageenan belongs to the glycosaminoglycan family alongside heparin, and heparin is known to inhibit real-time quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal swabs used to detect SARS-CoV-2. As heparin and carrageenan share structural similarities, this work aimed to investigate the interferent effect of carrageenan on RT-qPCR for SARS-CoV-2 detection across 4 different diagnostic platforms. This work demonstrated that in the presence of carrageenan samples return inaccurate and invalid results on the Seegene STARlet, while qualitative accuracy was maintained on the Cepheid GeneXpert, Roche Cobas LIAT, and Hologic Panther Aptima. Evidence of carrageenan interference on SARS-CoV-2 testing was consistent across two OTC brands and research-grade reconstituted iota-carrageenan, with 80% of results returning invalid regardless of the carrageenan formulation added to the samples. Further, a preliminary in vivo interference study demonstrated an increased Ct value within 15 minutes of carrageenan dosage, with Ct values restored 60 minutes post-application. A direct comparison of carrageenan- and heparin-mediated PCR interference demonstrated that carrageenan PCR interference occurs to a lesser degree, but is not reversible by the addition of heparinase I. As carrageenan is available OTC, interference with PCR testing that causes an increase in false negative results could lead to accidental spread of disease and could therefore have significant public health impacts on community testing of respiratory infectious diseases via PCR.